Market Research Report
Global Q Fever Market Research Report Forecast to 2023
|Published by||Market Research Future||Product code||882304|
|Published||Content info||105 Pages
Delivery time: 1-2 business days
|Global Q Fever Market Research Report Forecast to 2023|
|Published: June 30, 2019||Content info: 105 Pages||
Q fever is a mild disease with flu-like symptoms. In Q fever, the infection is caused by the bacterium Coxiella burnetii. Many patients have no symptoms at all, while, in some cases, the infection could reoccur/resurface years later. Chronic Q fever may damage the heart, liver, brain, lungs, and could cause diabetes in some cases.
The major factors driving the growth of the market include rising prevalence of Q fever coupled with increasing Q fever hospitalization rates, rising worldwide cattle, sheep, and goat population, growth in risk factors of Q fever, and globally growing geriatric population.
The global Q fever market has been segmented on the basis of type, diagnosis, treatment, end user, and region.
The global Q fever market, by type, has been segmented into acute and chronic.
The global Q fever market, by diagnosis, has been segmented into serology tests and others.
The global Q fever market, by treatment, has been segmented into antibiotics and surgery.
The global Q fever market, by end user, has been segmented into patients, hospitals and clinics, and others.
The global Q fever market is expected to reach a market value of USD 9,850.65 million by 2023 from USD 6,249.68 million in 2017 and is expected to register a CAGR of 7.83% during the forecast period of 2018 to 2023. In 2017, Asia-Pacific held the highest share of the market at 44.9%, followed by the Middle East and Africa with a share of 25.4%.
Merck KGaA, Teva Pharmaceutical Industries Ltd, Pfizer Inc., Basilea Pharmaceutica Ltd, Sanofi S. A., Melinta Therapeutics, Inc., Bayer AG, Johnson & Johnson Services, Inc., Yashica Pharmaceuticals, and AtoxBio.